3654 results for «372»

Filter By

3654 results

Radial and distal radial artery access for PCI

19 May 2026 – From EuroPCR 2026

This session provides an in-depth evaluation of radial and distal radial artery access for PCI, including a 20-year trend analysis of clinical outcomes, feasibility studies on distal radial interventions, and comparative real-world experiences. It also features meta-analyses of randomized trials on access approaches and early findings...

Devices and strategies in calcified lesions

21 May 2026 – From EuroPCR 2026

Explore advanced devices and techniques for treating calcified coronary lesions in this session. Discussions include the use of Eximer laser coronary atherectomy, novel cutting balloons, outcomes of rotational atherectomy in tortuous vessels, atherectomy combined with drug-coated balloon therapy, and calcium fracture patterns following Shockwave intravascular lithotripsy.

Treatment for calcified coronary artery disease in the real world

19 May 2026 – From EuroPCR 2026

This session presents real-world experiences and evidence on treating calcified coronary artery disease. It includes meta-analyses comparing rotational atherectomy and balloon angioplasty, long-term outcomes of excimer laser atherectomy, and multicenter registry data on intravascular lithotripsy (IVL), particularly in diabetic and high-risk patients. The session also focuses...

Addressing difficult anatomy in STEMI patients

21 May 2026 – From EuroPCR 2026

This session addresses the challenges of managing difficult coronary anatomy in STEMI patients through a series of complex case studies. Topics include management of aneurysms, rare aorto-ostial lesions, thrombosis interplay, PPCI in dextrocardia situs inversus, and hybrid PCI approaches for multifaceted coronary issues.

TAVI complications: impact and improvement

20 May 2026 – From EuroPCR 2026

This session examines critical complications associated with TAVI and strategies to mitigate their impact. Topics include carbon-dioxide flushing to reduce brain injury, management of cardiac tamponade, AI-driven customization of TAVI in complex anatomies, and the influence of vascular complications on post-procedural quality of life.

INOCA/ANOCA: technical aspects

20 May 2026 – From EuroPCR 2026

This session covers technical aspects critical to the evaluation and management of ischemia with non-obstructive coronary arteries (INOCA) and angina with non-obstructive coronary arteries (ANOCA). Key topics include the impact of guide catheter shape, injection techniques for thermodilution measurements, advanced perfusion CMR diagnostics, and the physiological...

FFR and non-hyperaemic pressure ratios

20 May 2026 – From EuroPCR 2026

This session presents contemporary clinical applications of fractional flow reserve (FFR) and non-hyperaemic pressure ratios (NHPR), highlighting real-world impacts of physiology microcatheter-based indices, the interplay between epicardial stenosis and microvascular resistance, post-PCI hyperemia effects on iFR, and machine-learning driven outcome predictions.

Other right-sided and tricuspid valve interventions

20 May 2026 – From EuroPCR 2026

This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.

Coronary sinus reducer for microvascular angina

28 Feb 2020

A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...

Coronary sinus reducer for microvascular angina

OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease

04 Nov 2021

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation – The WATCH-TAVR Trial

26 Oct 2023

Panos Xaplanteris provides his take on WATCH-TAVR results which were presented by Samir R. Kapadia at TCT Congress 2023.

Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial

Panagiotis Xaplanteris

Author

Panagiotis Xaplanteris
Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial

The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis

22 Mar 2022

Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022. 

Daniele Giacoppo

Author

Daniele Giacoppo
The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis

Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3

02 Apr 2025

Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.

Kalaivani Mahadevan

Author

Kalaivani Mahadevan
FFR-guided PCI vs CABG: 5-year results of the FAME 3 trial

Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR

29 Mar 2025

Daniele Giacoppo and Nicola Ammirabile provide their take on the main results of the HOST-BR trial, presented by Hyo-Soo Kim at ACC.25 in Chicago.

Nicola Ammirabile

Author

Nicola Ammirabile
Daniele Giacoppo

Author

Daniele Giacoppo
Harmonising optimal strategy for treatment of coronary artery diseases – bleeding risk: HOST-BR
Didn’t find what you were looking for?